#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Breast cancer metastatic Non-small cell lung cancer metastatic Type 2 diabetes mellitus More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Mucopolysaccharidosis III Anti-myelin-associated glycoprotein associated polyneuropathy Severe myoclonic epilepsy of infancy Palmoplantar pustulosis Osteochondrodysplasia Amyloidosis Infective uveitis Fms-like tyrosine kinase 3 positive Acute hepatic failure Renal disorder Allogenic stem cell transplantation Loeys-Dietz syndrome Anti-HLA antibody test positive Huntington's disease High-grade B-cell lymphoma More trials…

    Learn about Rare Diseases

    Activated PI3 kinase delta syndrome Crigler-Najjar syndrome – Treatment Kearns-Sayre syndrome – Treatment X-linked lymphoproliferative syndrome Lysosomal storage disorder – Trials in Disease Mucopolysaccharidosis I Systemic mastocytosis – Trials in Disease Atypical haemolytic uraemic syndrome – Diagnostics Richter’s syndrome – Trials in Disease Bronchiolitis obliterans syndrome – Treatment More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Aluminium Oxide Bupivacaine Cx-039776 Magrolimab Guselkumab Mitoxantrone Hydrochloride Ranibizumab USNOFLAST Romiplostim Pritelivir Propofol ELTANEXOR Dried Ferrous Sulfate Tuparstobart Tacrolimus Monohydrate Oxybutynin Sunvozertinib RNMB1 Gefitinib Agrostis Stolonifera Pollen More therapies…

    Learn about Your Condition

    Diabetic ketoacidosis Hyperthyroidism Cardiomyopathy Adenocarcinoma Gender dysphoria Pulmonary alveolar haemorrhage Hypothyroidism Left ventricular failure Retroperitoneal fibrosis Ichthyosis Endometrial adenocarcinoma Ventricular tachycardia Testicular germ cell cancer Breast cancer recurrent Peripheral ischaemia More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Krankenhaus Nordwest GmbH

Krankenhaus Nordwest GmbH

Sgalgrawobe Haps 2mrpk Pxkstghjjv Fnymqsbemz 6lmjfo Gjysjfg

Want to learn more about this study or check if you can participate? Contact us.

  • Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

    Recruiting

    3 1 1
    Investigated Drugs:
    • Calcium Folinate
    • Fluorouracil
    • Gemcitabine
    Austria Belgium Denmark Finland France Germany +6

  • Durvalumab plus drug combination as total neoadjuvant therapy for patients with resectable gastroesophageal adenocarcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Calcium Folinate
    • Docetaxel
    • Durvalumab
    Germany Spain

  • Study of precemtabart tocentecan alone or in drug combination versus standard therapy in previously treated metastatic colorectal cancer patients

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Bevacizumab
    • Tipiracil Hydrochloride
    • Trifluridine
    Austria Belgium Denmark France Germany Italy +3

  • Comparing Daraxonrasib Alone or Combined with Gemcitabine and Paclitaxel Albumin‑Bound vs Standard Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Pancreatic carcinoma metastatic
    Investigated Drugs:
    • (12M)-(1S,2S)-N-((63S,4S,Z)-11-ETHYL-12-(2-((S)-1-METHOXYETHYL)-5-(4-METHYLPIPERAZIN-1-YL)PYRIDIN-3-YL)-10,10-DIMETHYL-5,7-DIOXO-61,62,63,64,65,66-HEXAHYDRO-11H-8-OXA-2(4,2)-THIAZOLA-1(5,3)-INDOLA-6(1,3)-PYRIDAZINACYCLOUNDECAPHANE-4-YL)-2-METHYLCYCLOPROPANE-1-CARBOXAMIDE
    • Gemcitabine
    • Paclitaxel Albumin-Bound
    Austria Belgium Denmark France Germany Italy +5

  • Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastric cancer
    • Oesophageal adenocarcinoma
    Investigated Drugs:
    • Azd0901
    • Capecitabine
    • Fluorouracil
    Belgium France Germany Hungary Italy The Netherlands +2

  • INCA33890 With Standard Chemotherapy and Bevacizumab in First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Colorectal cancer metastatic
    Investigated Drugs:
    • Bevacizumab
    • Calcium Folinate
    • Fluorouracil
    Austria Belgium Denmark France Germany Italy +4

  • Volrustomig in Patients with Unresectable Pleural Mesothelioma and Esophageal Squamous Cell Carcinoma

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neoplasm
    Investigated Drugs:
    • Volrustomig
    • Cisplatin
    • Fluorouracil
    Germany Italy

  • A study of loxo-435, enfortumab vedotin, and pembrolizumab in adults with advanced or metastatic bladder cancer

    Recruiting

    3 1 1
    Investigated Diseases:
    • Bladder transitional cell carcinoma
    • Bladder cancer
    Investigated Drugs:
    • (S)-4-(4-(3-CHLORO-4-(1-(5-FLUOROPYRIDIN-2-YL)-2-HYDROXYETHOXY)PYRAZOLO[1,5-A]PYRIDIN-6-YL)-5-METHYL-1H-1,2,3-TRIAZOL-1-YL)PIPERIDINE-1-CARBONITRILE
    • Enfortumab Vedotin
    • Pembrolizumab
    Czechia Denmark France Germany Hungary Italy +3

  • A study of PF-08634404 and sigvotatug vedotin in patients with advanced solid tumors

    Recruiting

    1 1 1
    Investigated Diseases:
    • Squamous cell carcinoma of lung
    • Non-small cell lung cancer stage IV
    • Non-small cell lung cancer
    Investigated Drugs:
    • SIGVOTATUG VEDOTIN
    • HUMANISED IGG1 MONOCLONAL ANTIBODY AGAINST PD-L1 CONJUGATED TO MONOMETHYL AURISTATIN E VIA A VALINE-CITRULLINE LINKER
    France Germany Italy Spain

  • A study of PF-08634404 and a drug combination for adult patients with extensive-stage small cell lung cancer

    Recruiting

    4 1 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Atezolizumab
    • Carboplatin
    • Etoposide
    France Germany Italy Spain
1 2 3 … 14
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!